Could a common antifungal improve Crohn's therapy?
NCT ID NCT06274554
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding the antifungal drug fluconazole to standard IL-23 therapy helps people with mild to moderate Crohn's disease. About 120 adults will be randomly assigned to receive either fluconazole or a placebo alongside their usual treatment. The main goal is to see if more people achieve a significant reduction in symptoms after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluconazole (an antifungal drug) added to standard IL-23 therapy (risankizumab, guselkumab, or ustekinumab)
What this could lead to
If it works, this could point toward a way to make existing Crohn's treatments more effective by targeting gut fungi.
What could go wrong
This is a phase 3 trial, but it's still relatively small (120 people) and the benefit of adding an antifungal is unproven. Fluconazole can cause liver issues and drug interactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact